Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Down-regulation of CYP1A1 expression in breast cancer.

Hafeez S, Ahmed A, Rashid AZ, Kayani MA.

Asian Pac J Cancer Prev. 2012;13(5):1757-60.

2.

P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer.

Wazir U, Jiang WG, Yasaei H, Linne H, Newbold RF, Mokbel K.

Anticancer Res. 2013 May;33(5):2185-9.

PMID:
23645774
3.

Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.

Soufla G, Porichis F, Sourvinos G, Vassilaros S, Spandidos DA.

Cancer Lett. 2006 Apr 8;235(1):100-13.

PMID:
15949894
4.
5.
6.

Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors.

Karami-Tehrani F, Fallahian F, Atri M.

Tumour Biol. 2012 Dec;33(6):1927-32. doi: 10.1007/s13277-012-0453-9.

PMID:
22791569
7.

Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas.

Zhou W, Jiang Z, Liu N, Xu F, Wen P, Liu Y, Zhong W, Song X, Chang X, Zhang X, Wei G, Yu J.

J Cancer Res Clin Oncol. 2009 Jan;135(1):91-102. doi: 10.1007/s00432-008-0435-x.

PMID:
18670789
8.

miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.

Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.

Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.

9.

High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer.

Salhab M, Patani N, Jiang W, Mokbel K.

Breast Cancer. 2012 Apr;19(2):153-60. doi: 10.1007/s12282-010-0228-3.

PMID:
20972741
10.

MMP13 is potentially a new tumor marker for breast cancer diagnosis.

Chang HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ, Lin SR.

Oncol Rep. 2009 Nov;22(5):1119-27.

PMID:
19787229
11.

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.

Breast Cancer Res Treat. 2006 Feb;95(3):219-28.

12.

Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines.

Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R.

Breast Cancer Res Treat. 2002 Feb;71(3):249-55.

PMID:
12002343
13.

Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer.

Nie F, Yu XL, Wang XG, Tang YF, Wang LL, Ma L.

Int J Oncol. 2010 Nov;37(5):1261-9.

PMID:
20878073
14.
15.

Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis.

Chhabra A, Fernando H, Watkins G, Mansel RE, Jiang WG.

Oncol Rep. 2007 Oct;18(4):953-8.

PMID:
17786359
16.

Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis.

Ye L, Sun PH, Malik MF, Mason MD, Jiang WG.

J Cancer Res Clin Oncol. 2014 Jun;140(6):957-67. doi: 10.1007/s00432-014-1650-2.

PMID:
24667935
17.

[Expression and clinical significance of LRP16 gene in human breast cancer].

Liao DX, Han WD, Zhao YL, Pu YD, Mu YM, Luo CH, Li XH.

Ai Zheng. 2006 Jul;25(7):866-70. Chinese.

PMID:
16831279
18.

Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer.

Radpour R, Barekati Z, Haghighi MM, Kohler C, Asadollahi R, Torbati PM, Holzgreve W, Zhong XY.

Mod Pathol. 2010 May;23(5):763-72. doi: 10.1038/modpathol.2009.195.

19.

A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.

Mao H, Qu X, Yang Y, Zuo W, Bi Y, Zhou C, Yin H, Deng B, Sun J, Zhang L.

Mol Carcinog. 2010 Mar;49(3):283-9. doi: 10.1002/mc.20598.

PMID:
19937980
20.

Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.

Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W.

Clin Cancer Res. 2002 Oct;8(10):3065-74.

Items per page

Supplemental Content

Support Center